LNTH Lantheus Holdings Inc
Company Analysis
Latest News
Farallon Capital Reveals New $424M Stake in Lantheus Holdings
Hedge fund Farallon Capital Management established a new position in Lantheus Holdings (LNTH), a radiopharmaceutical company, according to its latest quarterly...
Lantheus Lands a New Alzheimer's Tool, but Does It Matter When the Company Is Already Headed for a Buyout?
Shares of Lantheus Holdings barely budged — trading at $100.91, virtually flat — after the company announced FDA approval of a new brain-imaging agent that...
Lantheus Wins FDA Approval for TAUKLARIFY to Detect Alzheimer’s Tau Pathology
Lantheus Holdings received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a new radiodiagnostic agent. The agent identifies tau neurofibrillary...
Lantheus Holdings Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Consensus Q2 2026 revenue is pegged at $362.4 million with an EPS of $1.11, while the stock currently trades at $102.64, trailing the average analyst price...
Lantheus to be Acquired by Curium for $102.50 Per Share Plus Contingent Payments
Lantheus Holdings, Inc. (LNTH) has entered into a definitive merger agreement to be acquired by Curium US Holdings LLC. Under the terms of the agreement,...
Lantheus Announces FDA Acceptance of Alzheimer's Imaging Agent NDA
Lantheus Holdings announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for MK-6240. MK-6240 is an...
Lantheus Faces Continued Scrutiny as Investor Lawsuit Deadline Looms
On October 14, 2025, Lantheus Holdings Inc. (LNTH) was prominently featured in financial news due to multiple law firms issuing reminders to investors about...